Zealand Pharma AS (OCSE:ZEAL) Change In Payables And Accrued Expense : kr0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Zealand Pharma AS Change In Payables And Accrued Expense?

Zealand Pharma AS's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2024 was kr0.00 Mil. It means Zealand Pharma AS's Accounts Payable & Accrued Expense stayed the same from Jun. 2024 to Sep. 2024 .

Zealand Pharma AS's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was kr0.00 Mil. It means Zealand Pharma AS's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

Zealand Pharma AS Change In Payables And Accrued Expense Historical Data

The historical data trend for Zealand Pharma AS's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma AS Change In Payables And Accrued Expense Chart

Zealand Pharma AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

17.06

119.94

-49.06

Zealand Pharma AS Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Zealand Pharma AS Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

Zealand Pharma AS Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Zealand Pharma AS's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (OCSE:ZEAL) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

ZLDPF:USA ZEALc:UK 0NZU:UK 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.